KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) EBIAT (2016 - 2026)

Eli Lilly filings provide 18 years of EBIAT readings, the most recent being $7.4 billion for Q1 2026.

  • On a quarterly basis, EBIAT rose 168.07% to $7.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $25.3 billion, a 127.59% increase, with the full-year FY2025 number at $20.6 billion, up 94.9% from a year prior.
  • EBIAT hit $7.4 billion in Q1 2026 for Eli Lilly, up from $6.6 billion in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $7.4 billion in Q1 2026 to a low of -$57.4 million in Q3 2023.
  • Median EBIAT over the past 5 years was $2.2 billion (2023), compared with a mean of $2.9 billion.
  • Biggest five-year swings in EBIAT: crashed 103.95% in 2023 and later skyrocketed 1790.42% in 2024.
  • Eli Lilly's EBIAT stood at $1.9 billion in 2022, then increased by 12.98% to $2.2 billion in 2023, then skyrocketed by 101.43% to $4.4 billion in 2024, then soared by 50.52% to $6.6 billion in 2025, then grew by 11.42% to $7.4 billion in 2026.
  • The last three reported values for EBIAT were $7.4 billion (Q1 2026), $6.6 billion (Q4 2025), and $5.6 billion (Q3 2025) per Business Quant data.